Market
Prescriptions surpassed 3 million within five months of launch, with 80% going to new patients Confident the drug will prove its value as more than weight loss amid competition with Lilly

Mike Doustdar, chief executive officer (CEO) of Novo Nordisk, expressed strong confidence in the company’s competition with Eli Lilly, buoyed by the successful launch of oral Wegovy, an obesity treatment.
According to biopharmaceutical news outlet Fierce Biotech on the 11th (local time), Doustdar said in an interview during the American Diabetes Association (ADA) 2026 Scientific Sessions, “I’m much more optimistic today than I was on the day I became CEO.”
His confidence stems from the explosive market response to oral Wegovy. Launched in the United States on January 5 this year, oral Wegovy surpassed 3 million cumulative prescriptions in just over five months. More than 80% of new prescriptions were for new patients with obesity who had never previously used a GLP-1 drug.
Doustdar took over as a potential savior in August 2025, when the company was facing a crisis, including a decline in its share price amid fierce competition with Eli Lilly’s Zepbound. “I thought Novo Nordisk needed to become more competitive,” he said. “As someone from the commercial side, my job is to compete and sell.”
He also directly rebutted concerns that the next-generation obesity treatment CagriSema produced less weight loss than Lilly’s tirzepatide, the active ingredient in Zepbound, in a head-to-head trial. CagriSema produced an average weight loss of 23% at week 84, compared with 25.5% for tirzepatide.
Doustdar said the results showed that “the world is obsessed with a single number—the weight-loss percentage.” He emphasized that CagriSema is a “best of both worlds” combination of semaglutide, the active ingredient in Wegovy and already proven to be the best-in-class drug, and a novel amylin analog, expressing confidence that the market would assess its value after launch.
For years, Novo Nordisk has emphasized the value of “more than weight loss,” including management of obesity-related complications such as reduced cardiovascular disease risk. Doustdar said, “In the past, the market may have wanted only high weight-loss numbers, so our message may have been ahead of its time,” but added, “Now, everyone at ADA is talking about managing complications. I’m convinced that our path was the right one.”
The company once experienced supply shortages because of explosive demand for Wegovy, but said it has now resolved the issue through global expansion of its manufacturing facilities and that its production capacity is “second to none.” In addition to CagriSema, Novo Nordisk is developing a range of follow-on pipeline candidates, including the GLP-1/amylin dual agonist zenagamtide and the triple agonist UBT251.

BIOBOOK TEAM
biobookmedia@biobook.co.kr
AstraZeneca’s new myasthenia gravis drug, cligepa, approved simultaneously in U.S. and EU

Biogen Invests $411 Million in Neurodegenerative Disease Drug Development

J&J to acquire Olin for $2.9 billion, taking on Roche’s Vabysmo

Lilly acquires rare blood cancer drug startup for up to $1.5 billion, its 15th deal this year

Seawolf Secures $100 Million and Signs $1.2 Billion DNA Therapeutics Deal With Sanofi

ROKIT Healthcare to Acquire Insolvent Rehabilitation Company for 7 Billion Won, Betting on a Platform